0843 GMT - Haleon's growth is a tale of two halves, with oral care strong and consumer healthcare weak, analysts at Bernstein say in a note. Its organic growth in oral care, at 8.8% for the third quarter, is starkly different from its consumer healthcare business, with respiratory slumping, they say. Overall, its underlying results are poor and are likely to raise questions around the longer-term sustainability of the business's growth profile, they add. Shares slumped 13.5% in early morning trading.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments